Group B Strep in Pregnancy: The 36-Week Test and Antibiotics

If your provider has mentioned a "GBS swab" or "strep B test" coming up at your next appointment, you are not alone in wondering what it involves and what a positive result would mean for your birth. Group B Strep (GBS) is one of those pregnancy topics that sounds alarming on its face — bacteria, antibiotics, risk to the baby — but becomes far less frightening once you understand what the science actually says. This guide walks you through the screening process, the intrapartum antibiotic protocol, and a few of the nuanced questions that come up in integrative medicine circles around microbiome effects and prevention.

This article is general health information and is not a substitute for personalized medical advice. Talk to your OB, midwife, or care team about your specific situation, test results, and birth plan.

What Is Group B Streptococcus, and How Common Is It in Pregnancy?

Group B Streptococcus (Streptococcus agalactiae; GBS) is a gram-positive bacterium that colonizes the gastrointestinal and genitourinary tracts of many healthy adults without producing any symptoms. It is not a sexually transmitted infection and it is not something you "caught" — it is simply a common commensal organism that may or may not be present at any given time.

In pregnant women, GBS colonization rates in the United States range from 10% to 30% of the population, with some older CDC-linked epidemiological literature placing the range at 15–35%, depending on ethnicity, geographic region, and age. The key clinical challenge is that colonization is dynamic: up to 40% of women who test GBS-positive at prenatal screening may test negative at the time of delivery. This means your culture result at 36–37 weeks is a snapshot, not a permanent state — and it is why the timing of the swab matters so much.

The risk GBS poses is almost entirely to the newborn. Vertical transmission from a colonized mother to her baby during a vaginal delivery occurs in approximately 50–70% of unprotected births, and of those exposed neonates, 1–2% develop invasive early-onset disease (EOD) — meaning meningitis, pneumonia, or sepsis in the first week of life. Before universal screening and intrapartum antibiotic programs were established in the early 1990s, neonatal GBS mortality reached 55%. The U.S. rate of GBS EOD today is approximately 0.23 per 1,000 live births, down from roughly 1.8 per 1,000 in the pre-prevention era — a 60–80% reduction directly attributable to IAP programs, per NCBI StatPearls.

Why Is the GBS Swab Done at 36–37 Weeks, and What Does the Test Involve?

The timing of universal GBS screening is not arbitrary — it is calibrated to the biology of colonization and the logistics of term delivery. ACOG's Committee Opinion on GBS prevention (originally published February 2020 and endorsed by the AAP, ACNM, AWHONN, and SMFM) recommends universal vaginal-rectal swab (VRS) culture screening at 36 0/7 to 37 6/7 weeks of gestation. The rationale: a culture collected during this window remains valid — meaning its negative predictive value holds — for up to five weeks, covering deliveries through 41 0/7 weeks of gestation. The negative predictive value of a GBS culture within that five-week validity period is 95–99%, making it highly reliable for informing intrapartum management.

This window was deliberately updated from the previous 35–37 week window specified in the 2010 CDC guidelines. Moving the screening a week later reduces false-negative results at later gestational ages, when most deliveries occur. The practical effect is that your test is more likely to reflect your colonization status at the time you actually go into labor.

The procedure itself is quick and straightforward. A sterile swab is used to collect a sample from the outer vaginal area and then the rectum — both sites are required because GBS colonizes the lower GI tract and can be present rectally even when the vaginal culture is negative. Many practices allow self-collection, which some women prefer. The swab is sent to a microbiology lab for culture, and results typically return within 24 to 48 hours. There is no blood draw and no speculum involved.

Two circumstances make the swab unnecessary because IAP is already indicated regardless of culture result: (1) GBS bacteriuria detected at any colony count during the current pregnancy, which signals heavy colonization; and (2) a previous infant who had invasive GBS disease. In both cases, your provider will proceed directly to intrapartum antibiotics.

What Happens During Labor If You Test GBS-Positive?

A positive GBS culture does not change your birth plan in terms of delivery mode. It is not an indication for cesarean section. What it does is add one specific step: intravenous antibiotics at the onset of labor (or at membrane rupture), continued until delivery. The one exception: if you are having a planned pre-labor cesarean with intact membranes, IAP is not required because the baby is not passing through the birth canal.

The Antibiotic Protocol

The preferred agent, per ACOG guidance and StatPearls, is intravenous penicillin G:

• Loading dose: 5 million units IV at the start of labor or membrane rupture
• Maintenance: 2.5 to 3 million units IV every four hours until delivery

Penicillin is chosen specifically for its narrow antimicrobial spectrum — it targets GBS effectively without broadly disrupting other bacterial populations, reducing the risk of selecting for resistant organisms. For women with a penicillin allergy, the protocol stratifies by allergy severity and GBS susceptibility:

Intrapartum GBS Antibiotic Protocol by Penicillin Allergy Status

Allergy Status	GBS Susceptibility	Recommended Agent	Dosing
No penicillin allergy	—	Penicillin G	5 MU load, then 2.5–3 MU q4h IV
Low anaphylaxis risk	—	Cefazolin	2 g load, then 1 g q8h IV
High anaphylaxis risk	Clindamycin-susceptible	Clindamycin	900 mg q8h IV
High anaphylaxis risk	Clindamycin-resistant	Vancomycin	20 mg/kg q8h IV, max 2 g/dose

Clindamycin resistance among U.S. GBS isolates runs 20–30%, so if you have a penicillin allergy, your provider will request susceptibility testing on your culture well before your due date. Do not wait until labor begins to have this conversation.

The optimal duration of IAP before delivery for maximal neonatal protection is four or more hours. Studies show that two hours of penicillin exposure meaningfully reduces GBS vaginal colonization counts and decreases clinical neonatal sepsis diagnoses — so obstetric interventions such as amniotomy or augmentation should never be delayed solely to achieve four hours of coverage. Your labor team will balance timing appropriately.

Approximately 31% of U.S. obstetric patients currently receive intrapartum GBS antibiotics, and prophylaxis efficacy is estimated at 86–89% — a remarkably high figure for a preventive intervention in obstetrics.

Unknown GBS Status and Special Circumstances in Labor

If you arrive in labor with unknown GBS status — because your result has not returned, you had no prenatal care, or you delivered before 36 weeks — your care team will assess several risk factors:

• Gestational age below 37 weeks
• Intrapartum fever
• Membrane rupture lasting more than 18 hours
• A previous infant with invasive GBS disease
• Documented GBS colonization in a prior pregnancy

Under current ACOG guidance, women with documented GBS colonization in a prior pregnancy are now considered candidates for IAP even without a current positive culture — a meaningful update from previous recommendations. If any of the above risk factors are present with unknown status, IAP will generally be initiated.

What About the Effect on the Baby's Gut Microbiome?

This question comes up frequently among women who are tuned in to the microbiome conversation, and it deserves a straightforward answer.

Yes, intrapartum penicillin has measurable effects on the infant gut microbiome during a developmentally sensitive window. Research published in 2025 in PubMed Central found that Bifidobacterium longum — a species associated with healthy infant gut colonization — was persistently reduced in IAP-exposed infants through one year of age. A 2017 analysis in Scientific Reports found lower bacterial species richness in IAP-exposed newborns early in life, though most recovery occurred by 12 weeks.

These findings are worth knowing. They are also best kept in proportion: the neonatal infection risk that GBS early-onset disease poses — meningitis and sepsis with historically catastrophic mortality — appropriately governs the treatment decision when colonization is confirmed. Women who receive IAP are encouraged to discuss postnatal probiotic support for themselves and their infant with their pediatrician after delivery. This is a conversation to have with your care team — not a reason to decline recommended antibiotics.

Can Anything Reduce Your Risk of Testing GBS-Positive?

The research here is genuinely interesting but not yet practice-changing. A study of 1,860 vaginal swabs found that Lactobacillus crispatus — a keystone species in a healthy vaginal microbiome — was associated with significantly lower GBS colonization rates (OR = 0.5, p < 0.001). A 2026 systematic review and meta-analysis found antenatal probiotic use associated with a 44% reduction in odds of a positive GBS culture (OR = 0.56), though evidence across individual trials was variable and no probiotic is FDA-authorized for this indication.

These findings are hypothesis-generating, not practice-defining. GBS colonization is dynamic — nearly half of GBS-positive women may test negative at delivery — and no antenatal intervention currently reliably or consistently prevents colonization at the time of labor. Do not use these findings to modify your screening or IAP plan. Bring them to your provider for a thoughtful, individualized conversation about supporting vaginal microbiome health through pregnancy as a complementary strategy.

The GBS swab at 36–37 weeks is a brief test with a large payoff: it gives your labor team the information they need to protect your newborn during one of the most vulnerable hours of their life. If you test negative, that result provides 95–99% negative predictive confidence through your expected delivery date. If you test positive, the intrapartum antibiotic protocol is well-established, highly effective, and will not change how or where you deliver.